The purpose of the trial is to test a potential new treatment for improving cognitive performance, including issues with memory, concentration, decision-making and the like.
This trial investigates the effectiveness of an oral medication called Xanamem® in improving cognitive symptoms in patients with MCI or mild or moderate dementia due to AD.
Xanamem was created to block the excess production of cortisol – the stress hormone – inside brain cells. High levels of cortisol are often seen in people with Alzheimer’s disease.
The trial medication is experimental.
®Xanamem is a registered trademark of Actinogen Medical Limited
Participation in the trial will be required for approximately 11.5 months (50 weeks). This includes a pre-screening period (if required) of 6 weeks, a screening period of up to 4 weeks, a treatment period of 9 months (36 weeks) and a follow-up period of 4 weeks.
‘Randomized’ means that you will be assigned by chance (like flipping a coin) to receive either the research project treatment or a placebo (no active ingredients).
‘Double-blind’ means neither doctor, participant, nor Actinogen will know which treatment was assigned at randomization.
Participants in the XanaMIA-B trial will need to:
There is no cost to participate in this clinical trial.
Reimbursement for reasonable travel and incidental costs incurred attending clinic visits will be provided.
Main participation criteria:
More details on the study, including the eligibility criteria, will be published on a public database soon.
Contact the nearest clinical trial site directly to discuss the trial and, if eligible, book a screening visit with the site.
This trial will start enrolling in Australia.
Locations will be updated once clinical trial sites are activated.
To learn more about the XanaMIA trial and/or to register interest, please contact firstname.lastname@example.org